Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
A Randomized, Double-blind, Two-arm, Parallel Group, Single-dose, Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Bundang-gu
-
Seongnam, Bundang-gu, Korea, Republic of, 13520
- CHA Bundang Medical Center
-
-
Jung-gu
-
Daejeon, Jung-gu, Korea, Republic of, 35015
- Chungnam National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male subject, between the ages of 28 and 55 years, both inclusive
- Subject had a body mass index (BMI) between 18.5 and 29.9 kg/m2, both inclusive, and a body weight between 50.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth.
- Subject with total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) and serum 25-OH vitamin D ≥ 20 ng/mL (≥ 50 nmol/L)
Exclusion Criteria:
- Subject was a female.
- Subject with a hypersensitivity to any component of denosumab or dry natural rubber (a derivative of latex).
- Subject was confirmed or suspected with infection of coronavirus disease 2019 (COVID-19) at screening, or had had contact with COVID-19 patient within 14 days from screening.
Subject had a medical history of and/or current medical condition that can have effect on the study. Details to be discussed with investigator as per Protocol.
- Subjects with known risk factors for hypocalcaemia
- Subjects with known intolerance to calcium or vitamin D supplements
- Subjects with known infection with active hepatitis B, hepatitis C, human immunodeficiency virus, or syphilis
- Subject had a history of and/or concurrent use of medications including any prior therapy that can have effect on the study. Details to be discussed with investigator as per Protocol.
- Subjects have or had any therapy that might significantly affect bone metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CT-P41
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
|
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
|
|
Active Comparator: US-licensed Prolia
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
|
a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
AUCinf
Time Frame: up to Day 253
|
Area under the concentration-time curve from time zero to infinity (AUC0-inf)
|
up to Day 253
|
|
AUClast
Time Frame: up to Day 253
|
Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)
|
up to Day 253
|
|
Cmax
Time Frame: up to Day 253
|
maximum serum concentration (Cmax)
|
up to Day 253
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CT-P41 1.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.